Figure S1. Effect of BI-69A11 on AKT signaling and cell viability in SW1 and MeWo cells.

Figure S2. BI-69A11 does not inhibit CHK2 in cells.

Figure S3. Effect of BI-69A11 on AKT signaling in SK-MEL-5 and UACC 903 cells.

Figure S4. Oral administration of BI-69A11 does not show overt toxicity.

Figure S5. Oral administration of BI-69A11 does not inhibit growth of SK-MEL-5 xenografts.

Figure S6. Inhibition of NF-kB signaling by BI-69A11 is independent of its effects on AKT.

Table S1. Status of cell lines used in this study.

Table S2. Blood chemistry following BI-69A11 p.o. administration (formulation 1, 6 doses).

PCMR_867_sm_FigS1.tif1371KSupporting info item
PCMR_867_sm_FigS2.tif718KSupporting info item
PCMR_867_sm_FigS3.tif575KSupporting info item
PCMR_867_sm_FigS4.tif7439KSupporting info item
PCMR_867_sm_FigS5.tif220KSupporting info item
PCMR_867_sm_FigS6.tif337KSupporting info item
PCMR_867_sm_AppS1.doc37KSupporting info item
PCMR_867_sm_TableS1-S2.doc53KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.